At relatively low doses, GLP-1-E2 has demonstrated beneficial effects in a PCOS mouse model of obesity, particularly in addressing metabolic dysfunction, including reductions in body weight and fat, as well as improvements in glucose management and insulin resistance, without causing uterine effects. This evidence concerns the gene GCG and obesity disorder.